NCT07096063Completed
Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk
Source: ClinicalTrials.gov · Last updated 15 Oct 2025
Brief summary (registry, in English)
Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 887132 (actual)
- First submitted
- 23 Jul 2025
- Start date
- 1 Oct 2024
- Primary completion date
- 15 Jul 2025
- Lead sponsor
- Brigham and Women's Hospital
- Diseases
- Type 2 diabetes
- NCT number
- NCT07096063
What you commit to
- Study type: Observational
- Participants enrolled: 887132
- From 1 Oct 2024 to the primary completion date, 15 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior use of pramlintide or any GLP-1-RA
- ELIGIBILITY FOR SEMAGLUTIDE VS SITAGLIPTIN
- Prior use of pramlintide or any GLP-1-RA or DPP4i
- ELIGIBILITY FOR TIRZEPATIDE VS SEMAGLUTIDE
- Prior use of pramlintide or any GLP-1-RA
Other illness
- Medullary thyroid carcinoma, MEN syndrome type 2
- Malignancy
- Type 1 diabetes or secondary diabetes
- Chronic kidney disease or dialysis
- Medullary thyroid carcinoma, MEN syndrome type 2
- Malignancy
- Type 1 diabetes or secondary diabetes
- Chronic kidney disease or dialysis
- Medullary thyroid carcinoma, MEN syndrome type 2
- Malignancy
- Type 1 diabetes or secondary diabetes
- Chronic kidney disease or dialysis
Other
- Uncontrolled diabetic retinopathy or maculopathy
- Pregnancy
- Uncontrolled diabetic retinopathy or maculopathy
- Pregnancy
- Uncontrolled diabetic retinopathy or maculopathy
- Pregnancy
Who the study is looking for
- History of MI, stroke, any surgical or percutaneous revascularization procedure, use of any antihypertensive/lipid-lowering drugs, coronary/carotid/peripheral artery disease, hypertension
- Type 2 diabetes
- BMI ≥25.0kg/m2
- Age ≥18 years
- Male or female sex
- History of MI, stroke, any surgical or percutaneous revascularization procedure, use of any antihypertensive/lipid-lowering drugs, coronary/carotid/peripheral artery disease, hypertension
- Type 2 diabetes
- BMI ≥25.0kg/m2
- Age ≥18 years
- Male or female sex
- History of MI, stroke, any surgical or percutaneous revascularization procedure, use of any antihypertensive/lipid-lowering drugs, coronary/carotid/peripheral artery disease, hypertension
- Type 2 diabetes
- BMI ≥25.0kg/m2
- Age ≥18 years
- Male or female sex
Criteria the registry did not label
- ELIGIBILITY FOR TIRZEPATIDE VS DULAGLUTIDE
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Brigham and Women's Hospital Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
Related publications
- Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice.Nat Med · 2026 · PMID 41207920
This page is information, not medical advice. Discuss any trial with your doctor.